EXUMA Biotech Corp.
StreetZero Signal 68
About EXUMA Biotech Corp.
EXUMA Biotech Corp. is a clinical‑stage biotechnology company developing next‑generation in vivo cell and gene therapies for cancer and autoimmune diseases. Based in West Palm Beach, Florida, the firm focuses on scalable, safe platforms such as its GCAR and Tumor Metabolism Regulated (TMR) CAR technologies. The company aims to lower the cost and complexity of cellular therapies while improving efficacy.
LATEST FUNDINGPrivate Placement
$70.0M
Announced 2026-08-20
TOTAL RAISED$70M
IN THE NEWS
- 🔗 EXUMA Biotech - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies - EXUMA Biotech
- 🔗 Press Releases & Mentions Archives - Page 3 of 4 - EXUMA Biotech
- 🔗 EXUMA Biotech
- 🔗 EXUMA Biotech Corp. - Drug pipelines, Patents, Clinical trials - Synapse
EMPLOYEES51-200
FOUNDED2015
HQWest Palm Beach, FL, USA
Industry
Biotechnology
Tags
BiotechnologyCell TherapyGene TherapyPrivate Placement
Key highlights
- $70 million private placement bolsters EXUMA's pipeline development
- The raise continues a track record of Series B funding from MSD Partners and SunTerra Capital
- EXUMA's GCAR and TMR CAR platforms aim to reduce therapy cost and improve safety
- Autologous subcutaneous CAR‑TaNK platform targets both hematologic and solid tumors
Tech stack
GCAR platformSynthetic CAR ligand (SCL)Tumor Metabolism Regulated (TMR) CARCAR‑TaNK platformCAR‑T and CAR‑NK technologies
Ask StreetZero about EXUMA Biotech Corp.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account